Cardiovascular robot systems maker Robocath has obtained its CE certification for its R-One robotic device, allowing it to begin commercialisation in Europe and the Middle East.
The robot assists interventional cardiologists in stenting (angioplasty) by enabling precision technologies that complement existing methods, in order to improve procedures and the working environment.
To achieve its objectives, Robocath is planning a new fundraising campaign, with the support of its historical shareholders, for the commercialisation of its device over the next few years.
Philippe Bencteux, chairman and founder of Robocath, said: “The whole Robocath team is proud to have taken this major step forward in our development, which comes just a few days after our first sale of a training robot to the Medical Training & Testing Center in Rouen. Our entry into the market for interventional vascular robotics represents a substantial opportunity for growth. There is the potential for the R-One solution to be installed in more than 3,000 procedure rooms, performing around 1.6 million interventions each year in Europe alone. Building on our CE mark, we expect to finalize a number of strategic distribution partnerships very shortly in high potential geographic areas, with a Europe and Middle-East wide launch expected in 2020.”
